Eczema Free Forever™ Eczema Free Forever™

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma


FiercePharma
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma
Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early

eczema – Google News

Sanofi’s eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat – FiercePharma


FiercePharma
Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
FiercePharma
But so far, the numbers on Sanofi's new eczema med look even better, according to Bill Sibold, EVP at Sanofi Genzyme. “Prescriptions are trending ahead of other recent biologic launches in dermatology, including Cosentyx,” Sibold said during the
Sanofi raises outlook but key eczema drug disappoints investorsReuters
France's Sanofi Raises Earnings Forecast, Pleased With Eczema Drug UptakeNew York Times
Sanofi raises outlook but key eczema drug disappoints investorsReuters UK

all 22 news articles »

eczema – Google News